Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OMEROS' : NARSOPLIMAB PIVOTAL TRIAL DATA TO BE SHARED AS AN ORAL PRESENTATION AT THE EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS

05/14/2021 | 07:24am EDT

SEATTLE - Omeros Corporation (Nasdaq: OMER) announced that data on organ function improvement from Omeros' pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress. The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult Patients with High-Risk Transplant-Associated Thrombotic Microangiopathy, will be delivered by Miguel-Angel Perales, M.D., Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center.

Dr. Perales' oral presentation will be available on demand through the EHA Virtual Congress platform to registered meeting attendees beginning Friday, June 11, 2021 at 9:00 am CEST / 3:00 am EDT. The presentation abstract (S241) can be accessed on EHA's website.

About Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a significant and often lethal complication of stem cell transplantation. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of HSCT-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 25,000 to 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an approximately 40-percent incidence of HSCT-TMA, and high-risk features may be present in up to 80 percent of these patients. In severe cases of HSCT-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae (e.g., dialysis) are common. There is no approved therapy or standard of care for HSCT-TMA.

About Narsoplimab

Narsoplimab, also known as 'OMS721,' is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

A biologics license application (BLA) is under priority review by the U.S. FDA for use of narsoplimab in the treatment of HSCT-TMA, and the drug is in Phase 3 clinical programs for immunoglobulin A (IgA) nephropathy and atypical hemolytic uremic syndrome (aHUS). Narsoplimab is also being evaluated for the treatment of COVID-19 as a part of the I-SPY-COVID-19 platform trial sponsored by Quantum Leap Healthcare Collaborative. The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy; and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders. Its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors. For more information about Omeros and its programs, visit www.omeros.com.

Contact:

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

T: 360.668.3701

E: jennifer@cwcomm.org

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about OMEROS CORPORATION
09/27OMEROS : Shares Sink After Receiving JPMorgan's Neutral Rating
MT
09/27OMEROS : JPMorgan Starts Omeros at Neutral With $15 Price Target
MT
08/09OMEROS : Q2 Loss Narrows on Rising Revenue -- Stock Up 3% After-Hours
MT
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
08/09OMEROS CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
08/09OMEROS CORPORATION : Reports Second Quarter 2021 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/03OMEROS CORPORATION : to Announce Second Quarter Financial Results on August 9, 2021
BU
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 112 M - -
Net income 2021 -121 M - -
Net Debt 2021 42,6 M - -
P/E ratio 2021 -7,65x
Yield 2021 -
Capitalization 908 M 908 M -
EV / Sales 2021 8,45x
EV / Sales 2022 5,36x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 14,53 $
Average target price 25,29 $
Spread / Average Target 74,0%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION1.72%908
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582